Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given their written agreement to take part voluntarily
• People aged between 18 and 75 years old, of any gender
• People who have been definitively diagnosed with a solid tumour (a cancer that forms a lump or mass) or acute leukaemia (a fast-moving blood cancer)
• People whose planned cancer treatment includes immunotherapy alone, immunotherapy combined with targeted therapy or chemotherapy, targeted therapy alone, targeted therapy combined with chemotherapy, or chemotherapy alone
• People whose general physical fitness is rated at a level where they are fully active, restricted in strenuous activity, or able to care for themselves but unable to carry out work (confirmed using a standard medical scoring system called ECOG, scores 0, 1, or 2)
• People whose blood cell counts at the screening stage are within acceptable ranges, indicating the bone marrow is functioning well enough (confirm specific values with trial site)
• People whose liver, kidney, lung, and blood-clotting functions are within acceptable ranges at screening (confirm specific values with trial site)
• Women of childbearing age who have a negative pregnancy test at screening
• All participants who are able to have children must agree to use effective contraception throughout the study and for at least one year after treatment ends

Who may not be able to join:

• People who have a known active autoimmune disease (where the immune system attacks the body) that is currently being treated
• People who stopped taking systemic steroid or hormone medications less than 2 weeks before joining the trial
• People who have previously had an organ or tissue transplant
• People who test positive for Hepatitis B surface antigen or Hepatitis B e antigen at screening
• People who test positive for certain Hepatitis B antibodies and also have detectable levels of Hepatitis B virus in their blood at screening
• People who test positive for Hepatitis C antibodies at screening
• People who test positive for syphilis antibodies at screening
• People who test positive for HIV antibodies at screening
• People who have detectable levels of Epstein-Barr virus (EBV) or cytomegalovirus (CMV) in their blood at screening
• People whose heart pumping function is below an acceptable level, or who have been diagnosed with serious heart failure (NYHA class III or IV)
• People with high blood pressure or pulmonary high blood pressure that has not been brought under control with standard treatment
• People who have had a heart attack or heart surgery within the 12 months before cell transfusion
• People with clinically significant heart valve problems
• People who have a cancer-related emergency at screening, such as a blockage in the bowel or compression of a blood vessel, that requires urgent treatment
• People who have active bleeding at the time of screening
• People who have had a blood clot in a deep vein or in the lungs within the 6 months before screening
• People who received a live vaccine within 6 weeks before screening
• People who have an active infection requiring treatment at the time of screening
• People who are unlikely to be able to follow the study requirements as directed

Important: Always verify eligibility with the trial site directly before applying.